Patents by Inventor MARIO PERRO

MARIO PERRO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD3/BCMA/CD38 Trispecific Antibodies
    Publication number: 20240132615
    Abstract: The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.
    Type: Application
    Filed: May 3, 2023
    Publication date: April 25, 2024
    Inventors: Maria PIHLGREN BOSCH, Mario PERRO, Olivia HALL, Laura CARRETERO IGLESIA, Adam DRAKE, Daniela PAIS, Rebecca CROASDALE-WOOD, Jérémy LOYAU, Carole ESTOPPEY, Ankita SRIVASTAVA, Michael DYSON, Julie MACOIN, Myriam CHIMEN, Thierry MONNEY, Cyrille DREYFUS
  • COMBINATION THERAPY OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS
    Publication number: 20240109976
    Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1 BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: June 13, 2023
    Publication date: April 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Claudia Ferrera Koller, Christian Klein, Mario Perro, Johannes Sam, Pablo Umaña, Wei Xu
  • COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATES AND FAP/4-1BB BINDING MOLECULES
    Publication number: 20240092856
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti-CEA/anti-CD3 bispecific antibody.
    Type: Application
    Filed: March 8, 2022
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Laura CODARRI DEAK, Sara COLOMBETTI, Christian KLEIN, Valeria G. NICOLINI, Mario PERRO, Johannes SAM, Christine TRUMPFHELLER, Pablo UMAÑA
  • COMBINATION THERAPY EMPLOYING A PD1-LAG3 BISPECIFIC ANTIBODY AND A CD20 T CELL BISPECIFIC ANTIBODY
    Publication number: 20240002546
    Abstract: The invention relates to combination therapies employing anti-PD1/anti-LAG3 bispecific antibody and a CD20 T cell-activating bispecific antibody, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Mario Perro, Patrick Alexander Aaron Weber
  • Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
    Patent number: 11718680
    Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: August 8, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Claudia Ferrara Koller, Christian Klein, Mario Perro, Johannes Sam, Pablo Umaña, Wei Xu
  • BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3
    Publication number: 20220259314
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 3, 2021
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Bispecific antibodies specific for PD1 and TIM3
    Patent number: 11130810
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: September 28, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
  • COMBINATION THERAPY OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS
    Publication number: 20200325238
    Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: March 16, 2020
    Publication date: October 15, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Claudia FERRARA KOLLER, Christian KLEIN, Mario PERRO, Johannes SAM, Pablo UMAÑA, Wei XU
  • BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3
    Publication number: 20190322748
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 24, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Bispecific antibodies specific for PD1 and TIM3
    Patent number: 10287352
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 14, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
  • BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3
    Publication number: 20170114135
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 29, 2016
    Publication date: April 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK